Why Is Stiripentol More Expensive Than Fenfluramine?
Stiripentol (Diacomit) typically costs $700–$1,200 per month for adults at standard doses (around 50 mg/kg/day), while fenfluramine (Fintepla) runs $500–$900 monthly for similar Dravet syndrome patients (0.4–0.7 mg/kg/day). Prices vary by dose, pharmacy, and insurance, but stiripentol averages 20–50% higher.[1][2]
Orphan Drug Pricing Pressures
Both drugs hold orphan designations for rare epilepsies like Dravet syndrome, granting 7 years of market exclusivity and tax credits that inflate U.S. launch prices. Stiripentol, approved by FDA in 2018 after EU approval in 2007, carries higher per-capsule costs ($10–$15 each) due to limited manufacturing scale—fewer than 5,000 U.S. patients qualify. Fenfluramine, relaunched in 2020 by a larger firm (UCB), benefits from optimized production and a liquid formulation reducing waste, trimming costs.[1][3]
Patent Protection and Generic Competition Timelines
Stiripentol's key U.S. patents (e.g., formulation patents expiring 2032–2035) block generics longer than fenfluramine's (core patents to 2027, with challenges possible by 2025). No generics exist for either yet, but fenfluramine faces earlier Paragraph IV challenges from companies like Amneal, potentially halving its price post-2027. Stiripentol's patents on its unique cyclodextrin formulation extend monopoly pricing.[4]
| Factor | Stiripentol | Fenfluramine |
|--------|-------------|--------------|
| Key Patent Expiry | 2032–2035 | 2027 |
| Generic Entry Risk | Low until 2030s | Medium by 2025–2027 |
Dosing, Administration, and Supply Chain Differences
Stiripentol requires 3–4 daily doses of powder capsules mixed with food, driving higher total volume and waste for kids. Fenfluramine's once- or twice-daily oral solution simplifies adherence and cuts pharmacy prep costs. Stiripentol's REMS program mandates specialist dispensing, adding $50–$100 monthly fees; fenfluramine's similar but broader distribution lowers per-patient overhead.[2][5]
Insurance Coverage and Patient Assistance Gaps
Medicare Part D covers both, but stiripentol hits donut holes faster due to higher list prices, with copays up to $500/month without aid. Fenfluramine's manufacturer coupons cap out-of-pocket at $5–$25 for commercials. Both offer copay cards, but stiripentol's smaller patient pool means less aggressive rebates to insurers, sustaining premiums.[1][6]
Clinical Monitoring and REMS Costs
Weekly ECGs and blood tests for fenfluramine (cardiac risk) add $200–$400 yearly, but stiripentol avoids routine cardiac monitoring, offsetting some expense. Both REMS programs restrict to certified centers, but stiripentol's powder stability issues increase spoilage and redispensing fees.[3][5]
[1]: GoodRx pricing data
[2]: Drugs.com cost comparisons
[3]: FDA labels for Diacomit and Fintepla
[4]: DrugPatentWatch.com - Stiripentol patents | Fenfluramine patents
[5]: Clinical guidelines from Epilepsy Foundation
[6]: Manufacturer patient assistance programs (Biocodex, UCB)